T-Cell-Associated Immunotherapy: A Promising Strategy for the Treatment of Hepatocellular Carcinoma

Ma, Weijie; Chen, Xi; Yuan, Yufeng

doi:10.2217/imt-2017-0053

Cited by 6 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, for patients in advanced-stage of HCC, unresponsive to sorafenib or with tumor recurrence, clinical options are yet very limited. In these cases, as well as in several other cancers unresponsive to the traditional chemotherapy, approaches of immunotherapy are promising (16). In particular, a targeted therapy of HCC with monoclonal antibodies able to induce an activation of the immune system and/or its escape from the inhibitory effects of tumor cells has been explored.…”

Section: Outline Of the Current Molecular Therapies Of Hccmentioning

confidence: 99%

Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma

Amicone¹,

Marchetti²

2018

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), is one of the most frequent human cancer and is characterized by a high mortality rate. The aggressiveness appears strictly related to the liver pathological background on which cancer develops. Inflammation and the consequent fibro/cirrhosis, derived from chronic injuries of several origins (viral, toxic and metabolic) and observable in almost all oncological patients, represents the most powerful risk factor for HCC and, at the same time, an important obstacle to the efficacy of systemic therapy. Multiple microenvironmental cues, indeed, play a pivotal role in the pathogenesis, evolution and recurrence of HCC as well as in the resistance to standard therapies observed in most of patients. The identification of altered pathways in cancer cells and of microenvironmental changes, strictly connected in pathogenic feedback loop, may permit to plan new therapeutic approaches targeting tumor cells and their permissive microenvironment, simultaneously.

show abstract

Section: Outline Of the Current Molecular Therapies Of Hccmentioning

confidence: 99%

Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma

Amicone¹,

Marchetti²

2018

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

show abstract

“…However, it is difficult to isolate TILs from the tumor tissues of HCC patients and expand them in vitro. In addition, only a few patients with HCC can tolerate lymphocyte deletion, which is essential before TIL infusion (62).…”

Section: Tumor-infiltrating Lymphocytes (Til)mentioning

confidence: 99%

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Liu

Liang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional therapeutic options that will help only a limited percentage of HCC patients. Cancer immunotherapy has achieved dramatic advances in recent years and provides new opportunities to treat HCC. However, HCC has various etiologies and can evade the immune system through multiple mechanisms. With the rapid development of genetic engineering and synthetic biology, a variety of novel immunotherapies have been employed to treat advanced HCC, including immune checkpoint inhibitors, adoptive cell therapy, engineered cytokines, and therapeutic cancer vaccines. In this review, we summarize the current landscape and research progress of different immunotherapy strategies in the treatment of HCC. The challenges and opportunities of this research field are also discussed.

show abstract

“…TILs can be expanded in vitro ; however, it is challenging to separate them from the tumor tissues of HCC patients. Additionally, only a small number of HCC patients can tolerate lymphocyte elimination, which is necessary prior to TIL infusion [ 56 ]. Chimeric antigen receptor T cell (CAR-T), a novel cancer immunotherapy in which T cells are genetically modified to recognize specific TAA, is the main research focus of ACT.…”

Section: Introductionmentioning

confidence: 99%

Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options

Panneerselvam,

Wilson,

Kumar

et al. 2023

Cell Adhesion & Migration

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the seventh most highly prevalent malignant tumor globally and the second most common cause of mortality. HCC develops with complex pathways that occur through multistage biological processes. Non-alcoholic fatty liver disease, metabolic-associated fatty liver disease, alcoholic liver disease, autoimmune hepatitis, hepatitis B, and hepatitis C are the causative etiologies of HCC. HCC develops as a result of epigenetic changes, protein-coding gene mutations, and altered signaling pathways. Biomarkers and potential therapeutic targets for HCC open up new possibilities for treating the disease. Immune checkpoint inhibitors are included in the treatment options in combination with molecular targeted therapy.

show abstract

T-Cell-Associated Immunotherapy: A Promising Strategy for the Treatment of Hepatocellular Carcinoma

Cited by 6 publications

References 20 publications

Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma

Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options

Contact Info

Product

Resources

About